FibroBiologics Announces Preliminary Proof of Concept for Fibroblast-based Diabetes Treatment - Seite 2

About FibroBiologics 

Based in Houston, FibroBiologics is a cell therapy and regenerative medicine company developing a pipeline of treatments and seeking potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 150+ US and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, wound healing, reversing organ involution, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy. For more information, visit www.FibroBiologics.com. 

Investor Relations: 
Nic Johnson or Harrison Seidner, Ph.D. 
Russo Partners 
[phone] 
[e-mail] 

Media Contact: 
Liz Phillips 
Russo Partners 
[phone] 
[e-mail] 

General Inquiries: 
[e-mail]

Logo - https://mma.prnewswire.com/media/1588786/4600873/FibroBiologics_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/fibrobiologics-announces-preliminary-proof-of-concept-for-fibroblast-based-diabetes-treatment-302092440.html

The FibroBiologics Stock at the time of publication of the news with a fall of -5,66 % to 8,66EUR on Tradegate stock exchange (18. März 2024, 22:26 Uhr).